Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway. Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer. The first-in-human study brings into the clinic a novel CELMoD or… Read More
Biotech company Shanghai Lishan has entered a licensing agreement with computational chemistry company Evogene for a treatment enhancing immunotherapy response. BMC128, a potential first-in-class, microbiome-based therapeutic, is designed to enhance anti-tumour activity. The treatment, developed by Evogene’s subsidiary Biomica, is a live biopharmaceutical consortium composed of four human gut bacterial strains with… Read More
Researchers at the Francis Crick Institute have mapped all the possible outcomes of changes to a tumour-suppressing gene called VHL. The VHL map could help clinicians work out which patients are at risk of developing kidney cancer or might respond to certain drugs. It… Read More
